SAN DIEGO, June 13, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharmaceutical company, has announced the presentation of clinical data supporting their investigational drug, rademikibart, at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress. The data, which demonstrates rademikibart's potential to significantly improve lung function and reduce annualized exacerbations in patients with eosinophilic-driven type 2 asthma, will be available from June 13-16, 2025, in Glasgow, United Kingdom, and virtually. These findings support ongoing Phase 2 acute exacerbation studies in asthma and chronic obstructive pulmonary disease (COPD), with topline data expected in the first half of 2026. Presentations are accessible on Connect Biopharma's website under the presentations and publications section.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。